{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:05:48Z","timestamp":1789441548588,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intravitreal injections (IVIs), a common treatment in ophthalmology, result in acute complications and urgent follow-up visits causing significant burden to both patient and physician. We evaluated the incidence of acute complications following IVIs which occurred within seven days of injection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study conducted at a private retinal practice, in Cleveland, Ohio. Using the practice management software database, we examined 73,286 injections of patients with unscheduled or urgent visits within 7\u00a0days of an injection from August 1st,2018 to August 1st,2020. Data collected included: age, gender, eye, medication injected, diagnosis, reason for urgent follow-up, time between injection and urgent follow-up, and type of anesthesia administered. Data was analyzed using SPSS v.28 (SPSS Inc., Chicago IL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Study included 73,286 injections, with 441 injections (n\u2009=\u2009441) resulting in urgent follow-up visits (0.60%). Mean patient age was 72.1 (\u00b1\u200930.4) years, with 187 male (42.4%) and 254 female (57.6%) patients. IVI medications included: aflibercept (60.3%), ranibizumab (22.4%), bevacizumab (13.4%), dexamethasone intravitreal implant (2%), triamcinolone acetonide (1.6%) brolucizumab (1.59%), fluocinolone acetonide intravitreal implant 0.19\u00a0mg (0.2%), and fluocinolone acetonide intravitreal implant 0.18\u00a0mg (0.03%) (Table 1). Medications associated with urgent visits included: aflibercept (42.9%), bevacizumab (37.4%), ranibizumab (7.9%), dexamethasone intravitreal implant (6.8%), brolucizumab (2.7%), and triamcinolone acetonide (2.3%) (Table 2). Days between injection and urgent follow-up was on average 3.96\u2009\u00b1\u20092.14\u00a0days. Urgent follow-ups included blurred vision in 164 patients (37.2% of urgent visits), flashes, floaters or posterior vitreous detachment (PVD) in 55 (12.5%), pain in 42 (9.5%), 43 (9.8%) corneal abrasions, 33 (7.5%) subconjunctival hemorrhages, corneal dryness or foreign body sensation in 30 (6.6%), endophthalmitis in 20 (4.5%), 18 (4.1%)vitreous hemorrhages, iritis or uveitis in 11 (2.5%), miscellaneous complications in 9 (2.0%), 7 (1.6%) elevated intraocular pressures, choroidal neovascular membrane in 4 (0.9%), 4 (0.9%) retinal detachments or tears, and 2 (0.45%) traumatic cataracts (Table 3).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IVIs resulted in 0.60% urgent\/unscheduled follow-up visits within 7\u00a0days of injection. Most common causes were blurred vision and symptoms of PVD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-021-00358-w","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T10:03:43Z","timestamp":1642500223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Analysis of urgent follow up visits and complications after intravitreal injections: a retrospective cohort study"],"prefix":"10.1186","volume":"8","author":[{"given":"Alexander","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Wilneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Yazji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Petrinec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"McCrossin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Donkor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-8496","authenticated-orcid":false,"given":"David G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"358_CR1","unstructured":"Williams GA: Review of ophthalmology: IVT injections: health policy implications. http:\/\/www.reviewofophthalmology.com\/content\/d\/retinal_insider\/c\/48732."},{"issue":"7","key":"358_CR2","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00417-010-1315-z","volume":"248","author":"BP Nicholson","year":"2010","unstructured":"Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):915\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9583","key":"358_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(07)61104-0","volume":"370","author":"TY Wong","year":"2007","unstructured":"Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet. 2007;370(9583):204\u20136.","journal-title":"Lancet"},{"key":"358_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/eye.2009.94","volume":"24","author":"KG Falavarjani","year":"2010","unstructured":"Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye. 2010;24:717\u20139.","journal-title":"Eye"},{"issue":"22","key":"358_CR5","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMcp1003934","volume":"363","author":"TY Wong","year":"2010","unstructured":"Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363(22):2135\u201344.","journal-title":"N Engl J Med"},{"key":"358_CR6","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.3928\/15428877-20120517-03","volume":"43","author":"ET Detorakis","year":"2012","unstructured":"Detorakis ET, Agorogiannis G, Drakonaki EE, Tsilimbaris MK, Pallikaris IG. Successful management of choroidal metastasis with intravitreal ranibizumab injection. Ophthalmic Surg Lasers Imaging. 2012;43:e47\u201351.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"4","key":"358_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3341\/kjo.2017.0036","volume":"31","author":"SJ Sheu","year":"2017","unstructured":"Sheu SJ. Endophthalmitis. Korean J Ophthalmol. 2017;31(4):283\u20139. https:\/\/doi.org\/10.3341\/kjo.2017.0036.","journal-title":"Korean J Ophthalmol"},{"key":"358_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000369478","volume":"233","author":"V Lemos","year":"2015","unstructured":"Lemos V, Cabugueira A, Noronha M, Abeg\u00e3o Pinto L, Reina M, Branco J, et al. Intraocular pressure in eyes receiving intravitreal antivascular endothelial growth factor injections. Ophthalmologica. 2015;233:162\u20138.","journal-title":"Ophthalmologica"},{"key":"358_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","volume":"34","author":"RL Avery","year":"2014","unstructured":"Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET Jr, D\u2019Amico DJ, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34:S1\u201318.","journal-title":"Retina"},{"key":"358_CR10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/eye.2012.199","volume":"26","author":"DA Lyall","year":"2012","unstructured":"Lyall DA, Tey A, Foot B, Roxburgh ST, Virdi M, Robertson C, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond). 2012;26:1517\u201326.","journal-title":"Eye (Lond)"},{"key":"358_CR11","doi-asserted-by":"crossref","unstructured":"Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118: 2028e2034.","DOI":"10.1016\/j.ophtha.2011.02.034"},{"key":"358_CR12","doi-asserted-by":"crossref","unstructured":"Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29: 313e318","DOI":"10.1097\/IAE.0b013e31819a5f98"},{"key":"358_CR13","doi-asserted-by":"crossref","unstructured":"Fileta JB, Scott IU, Flynn HW. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retin. 2014;45:143e149.","DOI":"10.3928\/23258160-20140306-08"},{"key":"358_CR14","doi-asserted-by":"crossref","unstructured":"Xu K, Chin EK, Bennett SR, et al. Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors: management and visual outcomes. Ophthalmology. 2018;125:1279e1286.","DOI":"10.1016\/j.ophtha.2018.05.025"},{"issue":"7","key":"358_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.oret.2020.09.024","volume":"5","author":"MS Ramos","year":"2021","unstructured":"Ramos MS, Xu LT, Singuri S, et al. Patient-reported complications after intravitreal injection and their predictive factors. Ophthalmol Retina. 2021;5(7):625\u201332. https:\/\/doi.org\/10.1016\/j.oret.2020.09.024.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"358_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4274\/tjo.galenos.2020.84042","volume":"51","author":"M Kaya","year":"2021","unstructured":"Kaya M, \u00d6ner FH, Akbulut Ya\u011fc\u0131 B, Ata\u015f F, \u00d6zt\u00fcrk T. Non-infectious intraocular inflammation following intravitreal anti-vascular endothelial growth factor injection. Turk J Ophthalmol. 2021;51(1):32\u20137. https:\/\/doi.org\/10.4274\/tjo.galenos.2020.84042.","journal-title":"Turk J Ophthalmol"},{"key":"358_CR17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2147\/OPTH.S35062","volume":"7","author":"B Tarlan","year":"2013","unstructured":"Tarlan B, Kiratli H. Subconjunctival hemorrhage: risk factors and potential indicators. Clin Ophthalmol. 2013;7:1163\u201370. https:\/\/doi.org\/10.2147\/OPTH.S35062.","journal-title":"Clin Ophthalmol"},{"key":"358_CR18","doi-asserted-by":"publisher","unstructured":"Laude A, Lim JW, Srinagesh V, Tong L. The effect of intravitreal injections on dry eye, and proposed management strategies. Clin Ophthalmol. 2017;11:1491\u20131497. doi: https:\/\/doi.org\/10.2147\/OPTH.S136500","DOI":"10.2147\/OPTH.S136500"},{"key":"358_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1475-1313.2009.00683.x","volume":"29","author":"MJ Doughty","year":"2009","unstructured":"Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt. 2009;29:573\u201383. https:\/\/doi.org\/10.1111\/j.1475-1313.2009.00683.x.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"6","key":"358_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/eye.2011.69","volume":"25","author":"CM Kumar","year":"2011","unstructured":"Kumar CM, Eid H, Dodds C. Sub-Tenon\u2019s anaesthesia: complications and their prevention. Eye (Lond). 2011;25(6):694\u2013703. https:\/\/doi.org\/10.1038\/eye.2011.69.","journal-title":"Eye (Lond)"},{"key":"358_CR21","doi-asserted-by":"crossref","unstructured":"Fagan XJ, Al-Qureshi S. Intravitreal injections: a review of the evidence for best practice. Clin Exp Ophthalmol. 2013;41: 500e507.","DOI":"10.1111\/ceo.12026"},{"key":"358_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, Schmidt-Erfurth U. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018;239:181\u201393. https:\/\/doi.org\/10.1159\/000486145.","journal-title":"Ophthalmologica"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00358-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-021-00358-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00358-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T10:08:09Z","timestamp":1642500489000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-021-00358-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1186\/s40942-021-00358-w","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was obtained for this retrospective study and was conducted in compliance with declaration of Helsinki as well as followed the Health Insurance Portability and Accountability Act (HIPAA) regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The Authors hereby grant the publisher permission to publish this work in International Journal of Retina and Vitreous. The Authors hereby confirms that this work has not been published before in any form and is not concurrently submitted to another publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}